← Back to Search

Other

AT193 for Hidradenitis Suppurativa

Phase 1
Waitlist Available
Research Sponsored by Azora Therapeutics Australia Pty Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a new treatment called AT193 to see if it is safe and effective for people with HS. The study will include about 44 participants and will last for a few months. The main goal is to check if AT193 is safe, and the secondary goal is to see if it helps improve HS symptoms.

Eligible Conditions
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AT193Experimental Treatment1 Intervention
Topical applied daily
Group II: PlaceboPlacebo Group1 Intervention
Topical applied daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AT193
2021
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Azora Therapeutics Australia Pty LtdLead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
~13 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top